Back to homepage

Immunology

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Authors: Karel Pavelka MD PhD, Zoltán Szekanecz MD PhD DSc, Nemanja Damjanov MD PhD, Branimir Anić MD PhD, Matija Tomšič MD PhD, Vadim Mazurov MD PhD, Marija Maksimovic MD, Orsolya Nagy MD PhD, Jerzy Świerkot MD PhD, Tzvetanka Petranova MD PhD, Tiina Veldi MD, Asta Baranauskaitė MD PhD, Catalin Codreanu MD PhD, Daina Andersone MD PhD, Roy Fleischmann MD

This post hoc analysis of SELECT-COMPARE reports, for the first time, the efficacy and safety of upadacitinib 15 mg in combination with methotrexate
(MTX) in patients from the Central and Eastern European region with MTX inadequate response rheumatoid arthritis compared with placebo or adalimumab with MTX up to 48 weeks of follow-up.

More▸

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance

Authors: Adam Kisling MD, Jason Jones MD, Caleb Hixson DO FCAP, David Hostler MD MPH FACP, Jordanna Hostler MD FACP

This article presents a case of ICEP in which mepolizumab was used as a steroid-sparing agent, resulting in improvement in markers of disease activity
and corticosteroid requirement.

More▸

Kawasaki disease in siblings and a review of drug treatment

Authors: Steven King-fan Loo MBChB, FRCP, Kam Lun Hon MBBS, MD, FAAP, FCCM, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP, Tak Cheung Yung MBBS, MRCPCH, Man Ching Yam MBChB, MRCPCH

This article describes the management of two siblings with KD
followed by a short review.

More▸

Pharmacological treatment of COVID-19: lights and shadows

Authors: Francesco Menzella MD, Mirella Biava Msc, Chiara Barbieri MD, Francesco Livrieri MD, Nicola Facciolongo MD

The aim of this review is to explore COVID-19 treatment options and describe the potential benefits or disadvantages of their use in severe cases.

More▸

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Authors: Sonam Puri MD, Michael Shafique MD

This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade in non-small-cell lung cancer (NSCLC).

More▸